BAEBIES, INC.
Durham, NC · Founded 2013 · CIK 0001650676 · Medtech · Private
FINDER®, a multifunctional diagnostic platform for rapid near-patient molecular, immunoassay, and coagulation tests
baebies.com →- Grants
- $45M
- 62 awards
- Sector median: 1
- Raised
- $77M
- 5 Form D · Sep 2025
- 12 months since last filing
- Contracts
- $5.9M
- 7 awards · Health and Human S, Defense
- #104 of 4531 in medtech
- Patents
- 25
- 3 granted · 22 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $13,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | $752,943 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Point-of-birth newborn screening for MCAD/VLCAD and galactosemia to eliminate deadly delays for time critical conditions | $254,130 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Multiplex platform for point-of-care newborn screening of hyperbilirubinemia | $692,126 | |
| Federal grant | Department of Health and Human Services · Phase II · Comprehensive, Near Patient Assessment of Severe Hypoglycemia in Newborns Using Low Blood Volume | $272,066 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid, Near Patient Nucleic Acid Testing for Congenital Cytomegalovirus (CMV) Infection | $763,182 | |
| Federal grant | Department of Health and Human Services · Phase II · Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | $611,918 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding thyroid testing in high risk newborns: total T3, free T4, TSH and TRAB | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-birth newborn screening for MCAD/VLCAD and galactosemia to eliminate deadly delays for time critical conditions | $1,614,387 | |
| Federal grant | Department of Health and Human Services · Phase II · Multiplex platform for point-of-care newborn screening of hyperbilirubinemia | $790,913 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | $224,903 | |
| Private capital raised | Form D · SEC | $12,761,733 | |
| Federal grant | Department of Health and Human Services · Phase II · A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies | $232,371 | |
| Federal grant | Department of Health and Human Services · Phase II · Comprehensive, Near Patient Assessment of Severe Hypoglycemia in Newborns Using Low Blood Volume | $767,573 | |
| Federal grant | Department of Health and Human Services · Phase II · Near Patient Acute Kidney Injury Biomarker Analysis in Critically Ill Neonates | $246,638 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid, Near Patient Nucleic Acid Testing for Congenital Cytomegalovirus (CMV) Infection | $708,578 | |
| Federal grant | Department of Health and Human Services · Phase I · A Rapid, Near Patient System for Small Blood Volume Testing of Ammonia, Glutamine and Glutamate to Support Recurrent Monitoring of Acute Neonatal Hyperammonemia | $231,134 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding thyroid testing in high risk newborns: total T3, free T4, TSH and TRAB | $916,266 | |
| Federal grant | Department of Health and Human Services · Phase I · Feasibility and validation of an integrated newborn screening algorithm with the targeted Next Generation Sequencing (tNGS) technology as part of a 2nd tier test for Pompe and MPS I | $215,022 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | $807,306 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-birth newborn screening for MCAD/VLCAD and galactosemia to eliminate deadly delays for time critical conditions | $696,600 | |
| Federal grant | Department of Health and Human Services · Phase II · A Low Blood Volume Platform for Global Newborn Screening of Common, Treatable Conditions | $215,300 | |
| Federal grant | Department of Health and Human Services · Phase II · Near Patient Acute Kidney Injury Biomarker Analysis in Critically Ill Neonates | $774,238 | |
| Federal grant | Department of Health and Human Services · Phase II · A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies | $710,423 | |
| Federal grant | Department of Health and Human Services · Phase I · An Innovative Unbound Bilirubin Assay to Identify Bilirubin-Induced Neurological Dysfunction (BIND) Risk as Part of a Comprehensive and Novel Point-of-Care Newborn Screening Panel | $215,743 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Expanding thyroid testing in high risk newborns: total T3, free T4, TSH and TRAB | $718,949 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | $692,626 | |
| Federal grant | Department of Health and Human Services · Phase II · Comprehensive, Near Patient Assessment of Severe Hypoglycemia in Newborns Using Low Blood Volume | $792,119 | |
| Federal grant | Department of Health and Human Services · Phase II · Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia | $1,938,885 | |
| Federal grant | Department of Health and Human Services · Phase II · A Low Blood Volume Platform for Global Newborn Screening of Common, Treatable Conditions | $697,715 | |
| Federal grant | Department of Health and Human Services · Phase II · ALow Blood Volume Platform for Global Newborn Screening of Common, Treatable Conditions | $1,415,106 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Workflow to Screen for Illicit Drug Exposure in Newborns | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Near Patient Acute Kidney Injury Biomarker Analysis in Critically Ill Neonates | $741,791 | |
| Federal grant | Department of Health and Human Services · Phase II · Feasibility and validation of an integrated newborn screening algorithm with targeted Next Generation Sequencing (tNGS) technology as part of a 2nd-tier test for Pompe and MPS I | $778,727 | |
| Federal grant | Department of Health and Human Services · Phase II · An Innovative Unbound Bilirubin Assay to Identify Bilirubin-Induced Neurological Dysfunction (BIND) Risk as Part of a Comprehensive and Novel Point-of-Care Newborn Screening Panel | $767,530 | |
| Federal grant | Department of Health and Human Services · Phase II · Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | $2,985,021 | |
| Federal grant | Department of Health and Human Services · Phase II · A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies | $666,412 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Workflow to Screen for Illicit Drug Exposure in Newborns | $716,018 | |
| Federal grant | Department of Health and Human Services · Phase II · A Low Blood Volume Platform for Global Newborn Screening of Common, Treatable Conditions | $717,391 | |
| Federal grant | Department of Health and Human Services · Phase II · Identification of glycosaminoglycans for newborn screening and therapeutic monitoring of mucopolysaccharidoses | $194,426 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | $214,063 | |
| Federal grant | Department of Health and Human Services · Phase II · Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia | $938,890 | |
| Federal grant | Department of Health and Human Services · Phase II · Feasibility and validation of an integrated newborn screening algorithm with targeted Next Generation Sequencing (tNGS) technology as part of a 2nd-tier test for Pompe and MPS I | $793,462 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | $278,148 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | $994,792 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · An Innovative Unbound Bilirubin Assay to Identify Bilirubin-Induced Neurological Dysfunction (BIND) Risk as Part of a Comprehensive and Novel Point-of-Care Newborn Screening Panel | $681,054 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | $2,654,326 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Workflow to Screen for Illicit Drug Exposure in Newborns | $672,757 | |
| Federal contract | Department of Health and Human Services · A Point-of-care Digital Microfluidic Platform For Diagnosis Of Viremic Hepatitis C Infection And Confirmation Of Cure Following Treatment | $1,799,981 | |
| Federal grant | Department of Health and Human Services · Phase II · Identification of glycosaminoglycans for newborn screening and therapeutic monitoring of mucopolysaccharidoses | $628,742 | |
| Private capital raised | Form D · SEC | $11,943,439 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | $878,833 | |
| Federal grant | Department of Health and Human Services · Phase II · Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | $995,038 | |
| Private capital raised | Form D · SEC | $37,568,813 | |
| Federal grant | Department of Health and Human Services · Phase II · A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | $266,110 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | $253,737 | |
| Federal grant | Department of Health and Human Services · Phase II · Identification of glycosaminoglycans for newborn screening and therapeutic monitoring of mucopolysaccharidoses | $703,049 | |
| Federal grant | Department of Health and Human Services · Phase I · A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase II · A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | $830,640 | |
| Federal contract | Department of Health and Human Services · Baebies Inc Multifunctional Analyzer For Point-of-need Testing By Clinic And Home Use | $749,960 | |
| Federal contract | Department of Health and Human Services · "a Multifunctional Point-of-care Platform To Differentiate Hiv Infection From Vaccine Induced Seropositivity" | $2,299,994 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | $863,466 | |
| Federal grant | Department of Health and Human Services · Phase II · A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | $948,080 | |
| Federal grant | Department of Health and Human Services · Phase II · A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | $998,891 | |
| Federal contract | Department of Health and Human Services · A Simple Multiplexed Platform For Self-administered Hiv And Hepatitis B Testing | $299,982 | |
| Federal contract | Department of Health and Human Services · SBIR 057 Sample-to-answer Detection Of Hepatitis C Virus | $243,499 | |
| Federal grant | Department of Health and Human Services · Phase II · A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance | $300,000 | |
| Federal contract | Department of Defense · Baebies Defense Health Agency Small Business Innovation Research Phase I Development Of A Wide Multiplexing, Multifunctional Platform For Flexible Diagnostics | $249,849 | |
| Federal grant | Department of Health and Human Services · Phase II · A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | $999,362 | |
| Federal contract | Department of Health and Human Services · Development Of A Rapid, Quantitative HIV-1 Assay For Viral Load Self-monitoring | $299,427 | |
| Federal grant | Department of Health and Human Services · Phase II · A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance | $1,000,723 | |
| Private capital raised | Form D · SEC | $2,049,923 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 101 | Whoop, Inc. | $6.3M | $177M |
| 102 | Electrical Geodesics, Inc. | $6.3M | — |
| 103 | Edwards Lifesciences Corp | $6.0M | $307M |
| 104 | BAEBIES, INC. | $5.9M | $77M |
| 105 | Lignamed, LLC | $5.9M | — |
| 106 | TIGER TECH SOLUTIONS INC | $5.9M | — |
| 107 | SILVER LAKE RESEARCH CORPORATION | $5.9M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Charles CadwellExecutive Officer
- William HawkinsDirector
- Lucy MartindaleExecutive Officer
- Nicholas NaclerioDirector
- Vamsee PamulaDirector · Executive Officer
- Dennis SachaDirector
- Richard WestDirector · Executive Officer
Patents
- Micro-regional Thermal Control For Digital Microfluidicsgranted
- Digital Microfluidics Multi-dynamic Range Parallel Biochemical Assaysgranted
- Microfluidics System, Device, And Methods For Performing Rapid Polymerase Chain Reaction (pcr) Protocolsapplication
- Microfluidics System, Device, And Methods For Performing Rapid Polymerase Chain Reaction (pcr) Protocolsgranted
- Digital Microfluidics (dmf) System, Cartridge, And Methods For Thermal Calibration Of Integrated Heaters And Sensorsapplication
- Culture Monitoring System And Methodsapplication
- Microfluidic Based Assay For Unbound Bilirubinapplication
- Digital Microfluidics Analytical Techniquesapplication
- Coagulation Assays For A Point-of-care Platformapplication
- Detection of Glycosaminoglycansapplication
- Digital Microfluidics Multi-dynamic Range Parallel Biochemical Assaysapplication
- Coagulation Assay For Point-of-care Platformapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.